Improving patient outcomes in heart failure: Evidence and barriers

Heart

Volumn 84, Issue SUPP, 2000, Pages

  Cleland, John G F ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; LISINOPRIL; LOSARTAN; PLACEBO; SPIRONOLACTONE; WARFARIN;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0033864229     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.84.suppl_1.i8     Document Type: Article

References (17)

1. Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J 1999;18:208-25.
2. Ho KK, Pinsky JL, Kannel WB et al. The epidemiology of heart failure, the Framingham Study. J Am Coll Cardiol 1993;22(4 suppl A):6A-13A.
3. Cleland JG, Gemmed I, Khand A, et al. Prognosis of heart failure improving? European Journal of Heart Failure 1999;1:229-41.
4. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the co-operative north Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987;316:1429-35.
5. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and J congestive heart failure. N Engl J Med 1991;325:293-302.
6. Monane M, Bohn RL, Gurwitz JH, et al. Noncompliance with congestive heart failure therapy in the elderly. 1994;154:433-7.
7. Philbin EF, Andreaou C, Rocco TA, et al. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol 1996;77:832-8.
8. Hillis GS, Trent RJ, Winton P, et al. Angiotensin-converting-enzyme inhibitors in the management of cardiac failure: are we ignoring the evidence? QJM 1996;89:145-50.
9. Hillis GS, Al-Mohammed A, Wood M, et al. Changing patterns of investigation and treatment of cardiac failure in hospital. Heart 1996;76:427-9.
10. Mair FS, Crowley TS, Bundred PE. Prevalence, aetiology and management of heart failure in general practice. Br J Gen Pract 1996;46:77-9.
11. Yusuf S, Phil D, Sleight P. Effects of an angiotensm-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
12. Cohn JN, Archibald DG, Zeische S, et al. Effect of vasodilator therapy on mortalilty in chronic congestive heart failure: results of a Veterans Administrative cooperative studv. N Engl J Med 1986;314:1547-52.
13. Cleland JG, McGowan J, Clarke A, et al. The evidence for beta-blockers in heart failure. BMJ 1999;318:824-5.
14. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure. The randomised aldactone evaluation study (RALES). Am J Cardiol 1996;78:902-7.
15. Topol E. ACE inhibitors still the drug of choice for heart failure. Lancet 1999;354:1797.
16. The ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting-enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-18.
17. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325: 303-10.